Bethesda, MD – National Institutes of Health (NIH)

Melanoma Clinical Trials- Recruiting Phase
NCT01264081
Lapatinib in Stage IV Melanoma With ERBB4 Mutations		 Phase II
NCT01271907
Drosophila-generated CTL		 Phase II
NCT00513604
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma		 Phase II
NCT01160445
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer		 Phase II
NCT01319565
Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI		 Phase II
NCT01118091
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M…		 Phase II
NCT00304460
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer		 Phase II
NCT00814684
Chemotherapy and Total-Body Irradiation Followed By Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Vaccine Therapy in Treating Patients With Metastatic Melanoma		 Phase II
NCT00665470
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma		 Phase II
NCT01369875
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma		 Phase II
NCT00670748
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer		 Phase II
NCT01369888
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma		 Phase I, Phase II
NCT01236573
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes		 Phase I, Phase II
NCT01273181
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes		 Phase I, Phase II
NCT01218867
Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes		 Phase I, Phase II
NCT00923390
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor		 Phase I, Phase II
NCT01021059
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer		 Phase I
NCT00923169
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)		 Phase I
NCT00492440
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer		 Phase I
NCT01313429
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum		 Phase I
NCT00792545
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery		 Phase I
NCT01336985
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads		 Phase I
NCT01366144
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction		 Phase I
NCT01341496
Tumor Cell Vaccines and ISCOMATRIX(Trademark) With Chemotherapy After Tumor Removal		 Phase I
NCT00556881
Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors		 Phase I
NCT00720785
Natural Killer Cells and Bortezomib to Treat Cancer		 Phase I
NCT01021059
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer		 Phase I
NCT00923169
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)		 Phase I
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.